04
GHK-Cu in creams and scalp preparations
Cosmetic hopes are ordinary enough. The useful question is which preparation produced a visible change, and how much of its reputation the small studies can carry.
Copper tripeptide-1
GHK joins glycine, histidine and lysine. With copper attached, it becomes GHK-Cu, also called Copper Tripeptide-1 in cosmetics. The distinction matters because binding copper changes the peptide’s behaviour. GHK occurs in human plasma and can be released as collagen breaks down during tissue turnover.
The 2015 skin-regeneration review describes plasma GHK falling from about 200 ng/mL at age 20 to about 80 ng/mL by age 60. It is easy to see the anti-ageing appeal in that observation. It supplies a reason to investigate; the health consequences of replacing the decline still require human evidence.
Collagen in skin studies
The 1988 human-fibroblast experiment found increased collagen synthesis in cells grown in dishes, without an increase in cell number. The individual cells were producing more. Later work examined collagen, elastin, water-holding materials and enzymes involved in tissue renewal; the 2008 review brings those repair findings together across several kinds of experiment.
The 2025 topical review reports increased procollagen production in 70% of GHK-Cu-treated subjects, compared with 50% for vitamin C and 40% for retinoic acid. Small topical trials also reported skin density, firmness, fine-line and wrinkle changes. Procollagen is an early form of collagen; a response rate for that measure says little about how large a visible change someone would notice.
The preparation and the visible result deserve more space than the ingredient’s reputation, to my mind. Small cosmetic studies can support a modest cosmetic interest while leaving the larger health claims open.
A hair preparation with two ingredients
The 2016 hair-growth trial followed 45 men with androgenetic alopecia, the common inherited pattern of hair loss, for 6 months. It tested a complex of 5-aminolevulinic acid and GHK. Hair-count gains were 52.6 with the 100 mg/mL preparation and 71.5 with 50 mg/mL, versus 9.6 with placebo. No adverse events appeared in any group.
This result is unusually specific: the lower-strength preparation had the larger reported count gain. That concentration result cannot carry a recommendation from me. Both preparations contained the combination, and the trial cannot assign the effect to GHK-Cu alone.
Skin entry
The 2025 review describes poor passage through the outer skin layer as a central problem. Chemical modification, delivery systems and microneedle pretreatment have been studied to improve it. Those experiments concern delivery, rather than instructions for a skincare routine.
In the 2011 skin-layer experiment, copper applied as GHK-Cu entered and crossed excised human skin over 48 hours. The skin retained a copper depot of 97 micrograms per square centimetre. These were skin samples in laboratory apparatus. Measuring copper movement there leaves the clinical effects and risks of a different route unresolved.
The 2018 gene-expression analysis operates at a different scale again: 59% of affected genes had higher expression and 41% lower expression. Protein-clearance gene counts were 41 up and 1 down. Those counts describe gene activity in cell and database work; they offer no measurement of an ordinary person’s recovery.
Irritation and untested routes
People describe smoother, firmer or more hydrated skin, softer fine lines, calmer-looking scars and less hair shedding. These are anecdotal impressions from community accounts, not clinical evidence. Pigment reports run in both directions: some describe more even colour, others darker or patchier marks. Irritation, stinging, itching, dryness, breakouts and a duller appearance also appear in reports.
The topical-delivery literature discusses instability with vitamin C and low-pH acids. Disrupting the copper complex can change its activity; free copper can promote oxidation. Those formulation questions are more specific than a general claim that copper peptides are gentle.
GHK-Cu is a legal cosmetic ingredient with no approved medical use here. Injectable, oral and other systemic uses remain unapproved and lack validated human pharmacokinetic evidence. Copper accumulation with prolonged systemic use is a theoretical concern, with no published human copper-toxicity cases attributed to GHK-Cu in this record. I’m unconvinced by transferring a cream’s history to a shot: the missing human exposure and safety data are substantial.
For the everyday comparison, the strongest direct human case remains small topical studies. The more expansive repair literature stays interesting on its own experimental terms.